Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
The Oncologist|August 19, 2022
DLL3 as an Emerging Target for the Treatment of Neuroendocrine NeoplasmsJames Yao, Emily Bergsland, Rahul Aggarwal, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)Taofeek K Owonikoko, Suzanne E Dahlberg, Saad A Khan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLCChristine L Hann, Timothy F Burns, Afshin Dowlati, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
The Oncologist|March 1, 2018
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung CancerKristen A Marrone, Xian Zhou, Patrick M Forde, et al.
Chemical Communications (Cambridge, England)|September 27, 2021
Azulene-based fluorescent chemosensor for adenosine diphosphateCarlos M López-Alled, Sang Jun Park, Dong Joon Lee, et al.
World Neurosurgery|December 1, 2019
Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory NeuroblastomaNyall R London, Lisa M Rooper, Justin A Bishop, et al.
Cancer Research|April 3, 2008
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancerChristine L Hann, Vincent C Daniel, Elizabeth A Sugar, et al.
The Journal of Pathology|June 14, 2021
AZD8055 enhances in vivo efficacy of afatinib in chordomasTianna Zhao, I-Mei Siu, Tara Williamson, et al.
Alimentary Pharmacology & Therapeutics|March 28, 2008
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis BS G Lim, N Leung, H W L Hann, et al.
Pageof 14